MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
3.850
-0.240
-5.87%
After Hours: 3.858 +0.008 +0.21% 18:56 08/10 EDT
OPEN
4.040
PREV CLOSE
4.090
HIGH
4.105
LOW
3.805
VOLUME
3.09M
TURNOVER
--
52 WEEK HIGH
40.37
52 WEEK LOW
2.960
MARKET CAP
222.96M
P/E (TTM)
-1.6645
1D
5D
1M
3M
1Y
5Y
1D
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
PR Newswire · 17h ago
Weekly Report: what happened at CAPR last week (0803-0807)?
Weekly Report · 18h ago
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
PR Newswire · 19h ago
Cisco, Tencent Headline Muted Earnings Week
Seeking Alpha · 2d ago
Capricor Therapeutics Lawsuit: CAPR Investors Focus on Alleged FDA Disclosure Issues and Stock Drops 
TipRanks · 3d ago
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
PR Newswire · 4d ago
CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Barchart · 4d ago
CAPR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026
Barchart · 5d ago
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.

Webull offers Capricor Therapeutics Inc stock information, including NASDAQ: CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.